SHERBOC [OPEN TRIAL]
A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in
Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy. Protocol: MM-121-02-02-10.
+ INFO